Novartis Data Demonstrates Efficacy of Ultibro Breezhaler

Novartis International AG / Novartis

data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149) . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. New analyses in the IGNITE clinical trial program showed that QVA149 provided superior, rapid and sustained improvements in lung function and significantly reduced shortness of breath versus comparator therapies[1],[2] BLAZE study also demonstrated significant improvements in shortness of breath with QVA149 compared to tiotropium 18 mcg in patients with moderate-to-severe COPD[3] SPARK study showed similar rates of reduction in exacerbations with once-daily Seebri® Breezhaler® (glycopyrronium bromide) and open-label tiotropium 18 mcg in patients with severe-to-very severe COPD[4],[5] Basel, September 8, 2013 - Novartis announced today new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators[1],[2].These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain. First results from